Rheumatology International

, Volume 29, Issue 3, pp 311–315 | Cite as

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study

  • Johann D. Ringe
  • Parvis Farahmand
  • Herbert Faber
  • Alfred Dorst
Original Article


The aim of this study was to assess the effect of treatment with risedronate 5 mg daily relative to control in men with primary or secondary osteoporosis over 2 years. Osteoporosis is a common condition in men that can have serious clinical consequences. In an earlier interim report, we found that 1 year of risedronate therapy resulted in significant increases in bone mineral density (BMD) and a significant reduction in vertebral fractures compared to control in men with osteoporosis. We conducted an open-label, prospective, match-control trial on men with primary or secondary osteoporosis in a single center, outpatient setting. Men with primary or secondary osteoporosis, as defined by a baseline lumbar spine BMD T-score ≤ −2.5 and a baseline femoral neck BMD T-score ≤ 2.0, were eligible for this study. Patients who had been treated with bisphosphonates or fluoride within the last 12 months were excluded. A total of 316 men were randomized to risedronate (n = 158) or control (n = 158). Patients were stratified by the presence of prevalent vertebral fractures at baseline and case by case allocated to either daily treatment with risedronate 5 mg daily plus calcium (1,000 mg) and vitamin D (800 IU) or to a control group (daily alfacalcidol (1 μg) plus calcium (500 mg) for those with prevalent vertebral fractures; daily vitamin D (800 IU) plus calcium (1,200 mg) for those without previous vertebral fractures). Primary study end points were identified prior to study initiation as the incidence of new vertebral fractures and changes in BMD at the lumbar spine, femoral neck, and total hip. Other end points included incidence of nonvertebral fractures and change in body height and back pain. Compared to control, the incidence of new vertebral fractures was significantly reduced in the risedronate 5 mg daily group at 2 years [14/152 (9.2%) for risedronate vs. 35/148 (23.6%) for control (61% risk reduction; P = 0.0026)]. Treatment with risedronate 5 mg daily also resulted in significant improvements in BMD at 2 years at all three skeletal sites (lumbar spine, 6.5 vs. 2.2%; femoral neck, 3.2 vs. 0.6%; total hip, 4.4 vs. 0.4% (P < 0.001 for all treatment comparisons). Significant reductions in the incidence of nonvertebral fractures (11.8 vs. 22.3%; P = 0.032), average loss in height, and back pain were also observed in risedronate-treated patients relative to control. In this 2-year study, daily 5 mg risedronate significantly reduced the risk of vertebral and nonvertebral fractures, improved BMD, decreased height loss, and reduced back pain in men with osteoporosis. Efficacy was sustained over 2 years; a consistent 60–61% risk reduction in vertebral fractures was observed at 1 and 2 years, respectively. These data demonstrate that daily risedronate is effective long-term therapy for men with primary or secondary osteoporosis.


Risedronate Male Osteoporosis Bisphosphonates Vertebral fracture Non-vertebral fracture 


  1. 1.
    Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, LondonGoogle Scholar
  2. 2.
    Ringe JD (2007) Treatment of osteoporosis in men. J Mens Health Gend (Elsevier) 4:326–333CrossRefGoogle Scholar
  3. 3.
    Seeman E (2004) Invest in your bones. Osteoporosis in men: the ‘silent epidemic’ strikes men too. International Osteoporosis Foundation, Available at http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/osteoporosis_in_men.pdf
  4. 4.
    Kaufman JM, Johnell O, Abadie E et al (2000) Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59:765–772. doi:10.1136/ard.59.10.765 PubMedCrossRefGoogle Scholar
  5. 5.
    Pande I, Scott DL, O’Neill TW, Pritchard C, Woolf AD, Davis MJ (2006) Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65:87–92. doi:10.1136/ard.2004.034611 PubMedCrossRefGoogle Scholar
  6. 6.
    Johnell O, Kanis JA, Odén A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42. doi:10.1007/s00198-003-1490-4 PubMedCrossRefGoogle Scholar
  7. 7.
    Gajic-Veljanoski O, Sebaldt RJ, Davis AM et al. (2007) Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis. Osteoporos Int (Epub ahead of print)Google Scholar
  8. 8.
    Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. A gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172. doi:10.1001/archinte.163.18.2165 PubMedCrossRefGoogle Scholar
  9. 9.
    Feldstein AC, Nichols G, Orwoll E et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16:953–962. doi:10.1007/s00198-005-1950-0 PubMedCrossRefGoogle Scholar
  10. 10.
    Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252–5255. doi:10.1210/jc.86.11.5252 PubMedCrossRefGoogle Scholar
  11. 11.
    Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610. doi:10.1056/NEJM200008313430902 PubMedCrossRefGoogle Scholar
  12. 12.
    Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427–431. doi:10.1007/s00296-005-0004-4 PubMedCrossRefGoogle Scholar
  13. 13.
    Ebeling PR (2008) Osteoporosis in men. N Engl J Med 358:1474–1482. doi:10.1056/NEJMcp0707217 PubMedCrossRefGoogle Scholar
  14. 14.
    Kamel HK (2005) Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 22:741–748. doi:10.2165/00002512-200522090-00003 PubMedCrossRefGoogle Scholar
  15. 15.
    Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: Recent advances with alendronate. Osteoporos Int 13:195–199. doi:10.1007/s001980200013 PubMedCrossRefGoogle Scholar
  16. 16.
    Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516. doi:10.1007/s00198-004-1713-3 PubMedCrossRefGoogle Scholar
  17. 17.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2006) Risedronate Is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. JBMR 21(Suppl 1):S110. doi:10.1359/jbmr.06s221 Google Scholar
  18. 18.
    Fransen M, Woodward M, Norton R, Robinson E, Butler M, Campbell AJ (2002) Excess mortality or institutionalization after hip fracture: men are at greater risk than women. J Am Geriatr Soc 50:685–690. doi:10.1046/j.1532-5415.2002.50163.x PubMedCrossRefGoogle Scholar
  19. 19.
    Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238. doi:10.1007/s00198-004-1811-2 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Johann D. Ringe
    • 1
  • Parvis Farahmand
    • 1
  • Herbert Faber
    • 1
  • Alfred Dorst
    • 1
  1. 1.Medizinische Klink IV, Klinikum LeverkusenTeaching Hospital of the University of CologneLeverkusenGermany

Personalised recommendations